Novel nasal spray effectively prevents influenza infection
Sep 25, 2024 · Cookie Type Duration Description; cookielawinfo-checkbox-advertising-targeting: persistent: 1 year: The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
Immuno-oncology innovations redefining cancer treatment in 2024
Jan 23, 2024 · Dr Espen Basmo Ellingsen. University of Oslo . Dr Ellingsen is a Medical Doctor and holds a PhD in cancer immunology from the University of Oslo. Background in translational research from the Institute for Cancer Research at Oslo University Hospital, focusing on therapeutic cancer vaccination, induced immune responses, and their impact on the tumor microenvironment.
The promise of vectors targeting the LDL receptor - Drug Target …
Jun 4, 2024 · What is the mechanism underlying RNA interference (RNAi) and how does it contribute to gene silencing in mammalian cells? The underlying mechanism of RNAi is based on the uptake by the cytoplasmic RNA-induced silencing complex (RISC) of small (21–24 nucleotides in length) interfering RNA (siRNA) that bind in a specific base-pairing manner with their complementary mRNA sequence, thereby ...
Developing an effective vaccine for herpes simplex virus
Feb 13, 2024 · Co-corresponding author Dr David Leib, chair and professor of microbiology and immunology at Geisel, explained: “Despite three decades of trying, the scientific community has been unable to develop an effective vaccine against herpes, and I think the main issue has been that we haven’t fully understood what we need, in terms of antibodies and their specific functions, to protect against ...
Prime editing corrects the CFTR gene mutation - Drug Target Review
Jul 22, 2024 · Cookie Type Duration Description; cookielawinfo-checkbox-advertising-targeting: persistent: 1 year: The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
Jun 18, 2024 · Mike Holmes, PhD, Chief Scientific Officer at Tessera Therapeutics. Michael joined Tessera in December 2021 as Chief Scientific Officer. Dr Holmes has over 20 years of experience working on the development and clinical translation of different genome editing- and gene therapy-based strategies for the treatment of inherited and acquired diseases.
Improving treatment response to KRAS inhibitors - Drug Target …
Nov 20, 2023 · Cookie Type Duration Description; cookielawinfo-checkbox-advertising-targeting: persistent: 1 year: The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
Exploring the potential of ADCs beyond oncology - Drug Target …
Aug 6, 2024 · Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers that will impact ADCs’ ability to make the shift from oncology to a broader ...
Eurofins Discovery - Drug Target Review
Integrated Drug Discovery.The DiscoveryOne™ integrated drug discovery team works hand-in-hand as partners with you, integrating all Eurofins Discovery capabilities to accelerate delivery of preclinical candidates by utilising our in-house project management and deep scientific expertise.
In vivo CAR T: Faster, cheaper, and more effective cancer care
Dec 16, 2024 · Recent advancements in ex vivo CAR T-cell therapies have revolutionised cancer treatment by harnessing the power of a patient’s own immune system to recognise and fight cancer. Treatment outcomes for large B-cell lymphoma were dismal before CAR T-cell therapies. After two relapses, fewer than 30 percent of patients responded to treatment, and the median overall survival was less than seven ...